SHANGHAI, CHINA – (BUSINESS WIRE) – NAMSA, the world’s only Medical Research Organization (MRO) that accelerates medical device development through integrated laboratory, clinical research and regulatory consulting services, is excited to announce the launch of its newly-developed website to serve as a new resource for Asia-Pacific (APAC) medical device sponsors.
The introduction of this highly-anticipated website is a direct result of the increased demand for NAMSA’s integrated medical device development services throughout China. Asia-Pacific’s second largest growth territory, China, is expected to grow steadily at a rate of 5.9 percent CAGR ‘18–’20 to $57B by 2022 (GlobalData).
“NAMSA China is pleased to introduce our first-ever Chinese language website to better serve our APAC clients. This user-friendly and information-filled resource will not only help support our significant growth in the region, but will also allow local manufacturers to more easily identify a proven, single source solution for efficient and cost-effective development and successful market introductions,” commented Samuel Tong, General Manager, NAMSA China.
NAMSA, with three locations throughout China, is consistently recognized as a leader within the Contract Research Organization (CRO) industry, and has a proven and established track record of delivering savings of up to 23 months and $17M+ throughout the product development continuum. For over 50 years, NAMSA has placed a dedicated focus on the judicious use of client resources and the delivery of high-quality development services, and has assisted thousands of customers to successfully launch life-changing medical products around the world.
Medical device manufacturers seeking NAMSA’s development and market access services in China are encouraged to visit our website here.
NAMSA is a Medical Research Organization (MRO), accelerating medical device product development through integrated laboratory, clinical research and regulatory consulting services. Driven by our regulatory expertise, NAMSA’s MRO® Approach plays an important role in translational research, applying a unique combination of disciplines—consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality—to move clients’ products through the development process, and continue to provide support through commercialization to post-market requirements anywhere in the world.
NAMSA operates 13 offices throughout North America, Europe, the Middle East and Asia, and employs nearly 1,000 highly-experienced laboratory, clinical and consulting Associates.